Leukaemia Immunophenotyping (Part 1) (Accredited)

This programme is run in conjunction with the Leukaemia Diagnostic Interpretation (Part 2) programme.


The purpose of this programme is to assess a laboratory’s ability to immunophenotype a leukaemia sample using flow cytometry and immunochemistry. This programme is designed to represent testing pathways in a clinical laboratory.


Please note that a laboratory who registers for Part One is automatically registered for Part Two and is required to complete both parts. However Part Two only registration is allowed for laboratories that do not routinely undertake immunophenotyping.


Individual registration for Part Two is also encouraged for continued professional development.


This part of the trial is designed to assess a laboratory’s ability to immunophenotype a leukaemia sample using flow cytometry and immunocytochemistry (where applicable). Participants are required to submit antigen expression for the core antigens on the malignant population in terms of positive or negative expression to allow generation of an overall immunophenotype. Performance is then monitored using comparison of the overall participant immunophenotype to the overall consensus immunophenotype. Participants are also able to submit results in terms of percentage antigen expression to allow for methodological comparison however thiese results are not performance monitored.


Stabilised blood obtained from consenting patients will be issued. This material can be readily analysed using whole blood lysis techniques. The samples are pre-diluted to give a leucocyte count of approximately 10x10^9/L, and so dilution to obtain a suitable white cell count for analysis is not required.


A digital blood smear for preliminary morphological analysis is also provided via our website and this image is intended to enable participants to determine which additional antigens they wish to test.


No blood film will be provided with the sample. Participants should not use the stabilised sample to make peripheral blood smears as the stabilisation process is designed to preserve the cells for flow cytometric analysis, and so this may result in aberrant blood film morphology that could be misleading.


This programme issues samples a minimum of 4 times per annum and a maximum of 6.


No activities in relation to this EQA programme are subcontracted.


To register for this programme, please click here.

Example Leukaemia Immunophenotyping Report
To view the annotations on this report, please download the PDF and view in a PDF reader such as Adobe Acrobat.
Example Leukaemia Immunophenotyping Repo[...]
Adobe Acrobat document [742.7 KB]
Leukaemia Immunophenotyping Performance Monitoring System
LI Performance Scoring System.pdf
Adobe Acrobat document [191.1 KB]
Print Print | Sitemap

Follow Us Online
Facebook Twitter LinkedIn Youtube


Last updated 31/03/2021 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information please click here.

Please click here for our privacy policy.

The UK NEQAS Organisation is a Company Limited by Guarantee (No.3012351) and a Registered UK Charity (No.1044013).